Health
FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.
OriginalSourceQuartzUnited StatesLeanUnratedCredibilityUnratedPublished18:50 UTCSourceQuartzUnited StatesLeanUnratedCredibilityUnratedPublished18:50 UTC
“FDA is requiring weight loss drug makers to add a vision loss warning”
“The warning covers all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a rare eye condition called NAION”
FDA requires vision loss warning on GLP-1 weight loss drug labels
Key points
- FDA mandates warning about NAION, an uncommon eye disorder risking permanent vision loss.
- Label changes apply to Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo.
- Warning appears in the Warnings and Precautions section of drug labeling.
- Meta-analysis found 6.4 NAION cases per 100,000 person-years on GLP-1 drugs.
- FDA reviewed trial and postmarketing data; no clear mechanism identified.
Other reports
- SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STATSourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
“STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition”
- SourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatchSourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatch
“Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP NewsSourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP News
- SourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington PostSourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington Post
“FDA tells GLP-1 makers to warn of potential vision loss side effect”
- SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York PostSourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post
“GLP-1 drugs must have new warning label over incurable blindness condition, says FDA”
- SourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at GizmodoSourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at Gizmodo
“FDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s”
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
How it got here
Quartz publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 9.
The Brief ranks it 9th.
9 9 FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.